CSL's 2026 Full Year Financial Results

Behind every breakthrough is a purpose. At CSL, our teams are advancing research that could improve the lives of people living with serious and rare conditions, including hereditary hemochromatosis, a genetic disorder that can lead to dangerous iron buildup in the body. When you join CSL, your work can help bring hope to patients around the world. Apply today: https://lnkd.in/gdJy4DQv #CSLCareers #LifeSciences #CSL

What does it take to turn scientific potential into real progress for patients? For Mollie Barrett, it starts with curiosity and a deep commitment to the people behind the science. Leading clinical operations for CSL’s hematology therapeutic area, Mollie helps transform promising research into well-executed clinical trials, bringing potential new treatments closer to patients with rare and complex blood disorders. From sickle cell disease to hemophilia, Mollie and her team navigate complex challenges every day, driven by the impact their work can have on patients’ lives. If you’re inspired to turn science into meaningful progress for patients, explore opportunities with CSL’s R&D team: https://lnkd.in/dbhEc33c #PeoplePoweringScience #CSLCareers #CSL

"If something isn’t working, you need to change course and create new opportunities....If it was easy, then anybody would do it. And that just feeds my curiosity even further." Hanna guides promising new therapies through regulatory approvals, translating the science into something health authorities can assess and approve as a new medicine for patients. Read Hanna's story here: https://lnkd.in/et-3RGzZ #CSL #PeoplePoweringScience

Plasma-derived medicinal products are gaining recognition as critical medicines. Most recently, Germany followed the United Kingdom in exempting PDMPs from an additional mandatory rebate. https://lnkd.in/g9hK2f7G #raredisease #plasma #patientaccess #CSL

Encouraging news for the hereditary angioedema \(HAE\) community: CSL announced positive top-line Phase 3b study results in children aged 2–11 years. Learn more in our newsroom: https://newsroom.csl.com

What does it take to lead clinical trials that could change lives? For Jeremy, it starts with patients. Early in his career, he saw firsthand the trust patients place in research. Today, he leads global clinical operations for a Phase 3 trial focused on preventing heart attacks in patients with end-stage kidney disease. That responsibility, and possibility, is what drives him. Join CSL’s R&D team and help make a meaningful impact for patients worldwide: https://lnkd.in/dbhEc33c #ClinicalResearch #PeoplePoweringScience #CSL #CSLCareers

Ready for a change? At CSL, your work can help advance innovative therapies that improve and save lives around the world. Join a team where curiosity is encouraged, growth is supported, and your contributions can make a meaningful impact. Explore opportunities to build what’s next in your career: https://lnkd.in/gdJy4DQv #CSLCareers #Innovation #LifeSciences #CSL

At CSL, we believe people living with hemophilia B, their families, caregivers and healthcare teams deserve timely, transparent communication. Today, we shared a community update reaffirming our commitment to the hemophilia B community and keeping stakeholders informed as new information becomes available. We thank the patient organizations, healthcare professionals, treatment centers and community advocates whose ongoing partnership helps strengthen support for those affected by hemophilia B. Read the full community letter: https://bit.ly/3ThnYv0 #HemophiliaB #RareDisease #PatientCommunity #DrivenByOurPromise